1. Home
  2. TALK vs ABVX Comparison

TALK vs ABVX Comparison

Compare TALK & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TALK
  • ABVX
  • Stock Information
  • Founded
  • TALK 2012
  • ABVX 2013
  • Country
  • TALK United States
  • ABVX France
  • Employees
  • TALK 521
  • ABVX N/A
  • Industry
  • TALK Medical/Nursing Services
  • ABVX
  • Sector
  • TALK Health Care
  • ABVX
  • Exchange
  • TALK Nasdaq
  • ABVX Nasdaq
  • Market Cap
  • TALK 476.8M
  • ABVX 511.3M
  • IPO Year
  • TALK N/A
  • ABVX N/A
  • Fundamental
  • Price
  • TALK $2.75
  • ABVX $6.57
  • Analyst Decision
  • TALK Buy
  • ABVX Buy
  • Analyst Count
  • TALK 6
  • ABVX 4
  • Target Price
  • TALK $4.50
  • ABVX $31.50
  • AVG Volume (30 Days)
  • TALK 2.4M
  • ABVX 261.5K
  • Earning Date
  • TALK 08-05-2025
  • ABVX 08-11-2025
  • Dividend Yield
  • TALK N/A
  • ABVX N/A
  • EPS Growth
  • TALK N/A
  • ABVX N/A
  • EPS
  • TALK 0.02
  • ABVX N/A
  • Revenue
  • TALK $194,359,000.00
  • ABVX $11,444,012.00
  • Revenue This Year
  • TALK $22.39
  • ABVX $284.20
  • Revenue Next Year
  • TALK $20.33
  • ABVX N/A
  • P/E Ratio
  • TALK $165.87
  • ABVX N/A
  • Revenue Growth
  • TALK 19.88
  • ABVX 128.98
  • 52 Week Low
  • TALK $1.60
  • ABVX $4.77
  • 52 Week High
  • TALK $4.36
  • ABVX $14.16
  • Technical
  • Relative Strength Index (RSI)
  • TALK 43.43
  • ABVX 48.50
  • Support Level
  • TALK $2.61
  • ABVX $5.69
  • Resistance Level
  • TALK $2.96
  • ABVX $6.75
  • Average True Range (ATR)
  • TALK 0.14
  • ABVX 0.45
  • MACD
  • TALK -0.04
  • ABVX -0.11
  • Stochastic Oscillator
  • TALK 27.21
  • ABVX 30.17

About TALK Talkspace Inc.

Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: